Drug intelligence / Profile preview

Bivalent CYD-2,4 dengue vaccine

Development stage: Unknown
Lead developer: Parent
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

The bivalent CYD-2,4 dengue vaccine is an experimental live attenuated vaccine candidate designed to induce immunity against two serotypes of the dengue virus—serotype 2 and serotype 4. It is based on the chimeric yellow fever-dengue (CYD) platform, where genes encoding structural proteins from the target dengue serotypes are inserted into a yellow fever 17D backbone. The primary mechanism of action is to stimulate neutralizing antibody responses against Dengue virus serotype 2 (DENV-2) and Dengue virus serotype 4 (DENV-4). This formulation was evaluated in clinical trials for immunogenicity and safety but did not show an advantage over tetravalent formulations in terms of immune response or protection. The developer behind this platform is Sanofi Pasteur[1].

Other names: CYD-2;4bivalent dengue vaccine (CYD-2;4)

Targets

DENV-1 antigens (Dengue virus serotype 1 antigens)prM (Zika virus precursor membrane protein)

Beyond the preview

Go deeper on Bivalent CYD-2,4 dengue vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bivalent CYD-2,4 dengue vaccine.